YTHDC1 inhibitor (Transition Bio)

Transition Bio's YTHDC1 inhibitor program focuses on developing small molecule inhibitors that target the YTH domain-containing protein 1 (YTHDC1). YTHDC1 is an m6A "reader" protein that, in certain cancers like acute myeloid leukemia (AML), localizes with m6A-marked RNAs in phase-separated biomolecular condensates. These condensates stabilize oncogenic transcripts, most notably MYC and BCL2, promoting tumor cell proliferation and survival. By blocking the interaction between YTHDC1 and m6A-modified RNAs, these small molecules disrupt the formation of these condensates, leading to the downregulation of MYC and other oncogenic drivers. The program is currently in the IND-enabling/lead optimization phase, with potential applications in MYC-driven cancers, including AML, prostate cancer, and small cell lung cancer.

Other names

YTHDC1-MYC programYTHDC-1-MYC programYTHDC 1-MYC programYTHDC1 inhibitorsYTHDC-1 inhibitorsYTHDC 1 inhibitors